Migraine drug takes on pancreatic cancer in early trial
NCT ID NCT07475234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding the migraine drug rimegepant to standard chemotherapy can help people with metastatic pancreatic cancer. About 30 adults who have not had prior treatment will receive the combination. Researchers will track how long the cancer stays under control and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rimegepant (a migraine drug) combined with nab-paclitaxel and gemcitabine (standard chemotherapy)
What this could lead to
If it works, this could point toward a new first-line treatment option for metastatic pancreatic cancer, potentially slowing disease progression.
What could go wrong
This is a very early, small trial (30 people) with no control group. The drug combination may not work better than standard care, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••